Takeuchi Shinji 竹内伸司

… Alternative Names

TAKEUCHI SHINJI 竹内伸司

TAKEUCHI Shinji 竹内伸司

Less

Researcher Number	90565384
Other IDs
External Links
Affiliation (Current)	2025: 金沢大学, 附属病院, 講師
Affiliation (based on the past Project Information) *help	2017 – 2023: 金沢大学, 附属病院, 講師 2015: 金沢大学, がん進展制御研究所・腫瘍内科, 助教 2011 – 2014: 金沢大学, がん進展制御研究所, 助教
Review Section/Research Field	Principal Investigator Respiratory organ internal medicine / Basic Section 53030:Respiratory medicine-related Except Principal Investigator Respiratory organ internal medicine / Basic Section 50020:Tumor diagnostics and therapeutics-related
Keywords	Principal Investigator アポトーシス / HDAC阻害薬 / EGFR変異肺がん / BIM遺伝子多型 / EGFR変異 / 肺癌 / 肺がん / ALK融合遺伝子 / STAT3 / ALK肺がん … More / トランスレーショナルリサーチ / 癌 / HDAC3 / Osimertinib / 非小細胞肺癌 / apoptosis / EGFR-TKI / BIM / 活性酸素 / ROS / Ras … More Except Principal Investigator EMT / 薬剤耐性 / miR-200 / ALK融合遺伝子陽性肺癌 / HDAC阻害薬 / ALK / 耐性 / osimertinib / miR200c / GSK-3 / オシメルチニブ / 肺がん / EGFR / 第3世代-TKI / EGFR変異肺癌 / AXL / EGFR肺癌 / ゲフィチニブ / 上皮成長因子受容体 / 線維芽細胞 / MET / 肝細胞増殖因子 / 公子標的治療 / PI3K / バイオマーカー / EGFR遺伝子変異 / Met / HGF / EGFR-TKI / 肺癌 Less

Development of Novel Therapies Targeting Apoptosis Resistance Factors in ALK-rearranged Lung CancerPrincipal Investigator
- Principal Investigator
  
  Takeuchi Shinji
- Project Period (FY)
  2020 – 2023
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 53030:Respiratory medicine-related
- Research Institution
  Kanazawa University
Development of treatment to overcome TKI resistance caused by EMT in lung cancer
- Principal Investigator
  
  Fukuda Koji
- Project Period (FY)
  2018 – 2020
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 50020:Tumor diagnostics and therapeutics-related
- Research Institution
  Kanazawa University
Development of therapy for overcoming resistance to mutant selective EGFR-TKI due to persistance of apoptosisPrincipal Investigator
- Principal Investigator
  
  TAKEUCHI SHINJI
- Project Period (FY)
  2017 – 2020
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Respiratory organ internal medicine
- Research Institution
  Kanazawa University
Development of therapies for overcoming EMT-associated irreversible tyrosine kinase inhibitor resistance in EGFR lung cancer
- Principal Investigator
  
  Fukuda Koji
- Project Period (FY)
  2014 – 2015
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Respiratory organ internal medicine
- Research Institution
  Kanazawa University
Development of therapy for circumvention of EGFR-TKI resistance due to BIM polymorphism in EGFR mutant lung cancer.Principal Investigator
- Principal Investigator
  
  TAKEUCHI Shinji
- Project Period (FY)
  2013 – 2014
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Respiratory organ internal medicine
- Research Institution
  Kanazawa University
Development of novel targeted therapy for lung cancer with activating Ras mutationPrincipal Investigator
- Principal Investigator
  
  TAKEUCHI Shinji
- Project Period (FY)
  2011 – 2012
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Respiratory organ internal medicine
- Research Institution
  Kanazawa University
Development of individual therapy for overcoming HGF-induced molecular targeted drug-resistance in EGFR-mutant lung cancer
- Principal Investigator
  
  YANO Seiji
- Project Period (FY)
  2009 – 2011
- Research Category
  
  Grant-in-Aid for Scientific Research (B)
- Research Field
  
  Respiratory organ internal medicine
- Research Institution
  Kanazawa University

All 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 Other

All Journal Article Presentation Book Other

[Book] 分子呼吸器病2014
- Author(s)
  竹内伸司、矢野聖二
- Publisher
  先端医学社
- Data Source
  KAKENHI-PROJECT-25860640
[Book] Biotherapy 25巻5号2011
- Author(s)
  竹内伸司, 矢野聖二
- Publisher
  がんと化学療法社
- Data Source
  KAKENHI-PROJECT-23790903
[Journal Article] STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis.2022
- Author(s)
  Yanagimura N, Takeuchi S, Fukuda K, Arai S, Tanimoto A, Nishiyama A, Ogo N, Takahashi H, Asai A, Watanabe S, Kikuchi T, Yano S.
- Journal Title
  
  NPJ Precis Oncol
  
  Volume: 6 Issue: 1 Pages: 11-11
- DOI
  10.1038/s41698-022-00254-y
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-18KT0019, KAKENHI-PROJECT-19H03665, KAKENHI-PROJECT-21H02609, KAKENHI-PROJECT-20K08516, KAKENHI-PROJECT-23K20323
[Journal Article] Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)2021
- Author(s)
  Takeuchi Shinji、Yanagitani Noriko、Seto Takashi、Hattori Yoshihiro、Ohashi Kadoaki、Morise Masahiro、Matsumoto Shingo、Yoh Kiyotaka、Goto Koichi、Nishio Makoto、Takahara Shizuko、Kawakami Takahiro、Imai Yasuhito、Yoshimura Kenichi、Tanimoto Azusa、Nishiyama Akihiro、Murayama Toshinori、Yano Seiji
- Journal Title
  
  Translational Lung Cancer Research
  
  Volume: 10 Issue: 1 Pages: 314-325
- DOI
  10.21037/tlcr-20-549
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K08516, KAKENHI-PROJECT-19K08625, KAKENHI-PROJECT-19K07910
[Journal Article] Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.2020
- Author(s)
  Shinji Takeuchi, Tetsunari Hase, et al.
- Journal Title
  
  Cancer science
  
  Volume: 111 Issue: 2 Pages: 561-570
- DOI
  10.1111/cas.14260
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17K09649, KAKENHI-PROJECT-19H03665, KAKENHI-PROJECT-18K07443
[Journal Article] MET amplification results in heterogeneous responses to osimertinib in EGFR ‐mutant lung cancer treated with erlotinib2020
- Author(s)
  Nishiyama Akihiro、Takeuchi Shinji、Adachi Yuta、Otani Sakiko、Tanimoto Azusa、Sasaki Motoko、Matsumoto Shingo、Goto Koichi、Yano Seiji
- Journal Title
  
  Cancer Science
  
  Volume: 111 Issue: 10 Pages: 3813-3823
- DOI
  10.1111/cas.14593
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K08516, KAKENHI-PROJECT-19H03665, KAKENHI-PROJECT-18K06985
[Journal Article] Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism2020
- Author(s)
 Arai S, Yano S, et al.
- Journal Title
 
 J. Med. Invest.
 
 Volume: 67 Issue: 3.4 Pages: 343-350
- DOI
 10.2152/jmi.67.343
- NAID
 130007936892
- ISSN
 1343-1420, 1349-6867
- Language
 English
- Peer Reviewed
- Data Source
 KAKENHI-PROJECT-19H03665, KAKENHI-PROJECT-17K09649
[Journal Article] Glycogen synthase kinase‐3 inhibition overcomes epithelial‐mesenchymal transition‐associated resistance to osimertinib in EGFR ‐mutant lung cancer2020
- Author(s)
  Fukuda Koji、Takeuchi Shinji、Arai Sachiko、Kita Kenji、Tanimoto Azusa、Nishiyama Akihiro、Yano Seiji
- Journal Title
  
  Cancer Science
  
  Volume: 111 Issue: 7 Pages: 2374-2384
- DOI
  10.1111/cas.14454
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-20K08516, KAKENHI-PROJECT-19H03665, KAKENHI-PROJECT-18K07261
[Journal Article] Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression2020
- Author(s)
  Tanimoto Azusa、Matsumoto Shingo、Takeuchi Shinji、Arai Sachiko、Fukuda Koji、Nishiyama Akihiro、Yoh Kiyotaka、Ikeda Takaya、Furuya Naoki、Nishino Kazumi、Ohe Yuichiro、Goto Koichi、Yano Seiji
- Journal Title
  
  Clinical Cancer Research
  
  Volume: 27 Issue: 5 Pages: 1410-1420
- DOI
  10.1158/1078-0432.ccr-20-2853
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K08516, KAKENHI-PROJECT-19H03665, KAKENHI-PROJECT-18K15922
[Journal Article] GSK-3 inhibition overcomes EMT-associated resistance to osimertinib in EGFR mutant lung cancer2020
- Author(s)
  Koji Fukuda, Shinji Takeuchi, Sachiko Arai, Kenji Kita, Azusa Tanimoto, Akihiro Nishiyama, Seiji Yano
- Journal Title
  
  Cancer Science
  
  Volume: -
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-18K07261
[Journal Article] Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer.2020
- Author(s)
  Sachiko Arai, Shinji Takeuchi, Koji Fukuda, Hirokazu Taniguchi, Akihiro Nishiyama, Azusa Tanimoto, Miyako Satouchi, Kaname Yamashita, Koshiro Ohtsubo, Shigeki Nanjo, Toru Kumagai, Ryohei Katayama, Makoto Nishio, Mei-Mei Zheng, Yi-Long Wu, Hiroshi Nishihara, Takushi Yamamoto, Mitsutoshi Nakada, Seiji Yano
- Journal Title
  
  Journal of thoracic oncology
  
  Volume: 15 Issue: 5 Pages: 752-765
- DOI
  10.1016/j.jtho.2020.01.001
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17K09649, KAKENHI-PROJECT-19K16738, KAKENHI-PROJECT-19H03524
[Journal Article] Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status.2019
- Author(s)
  Fukuda K, Takeuchi S,Yano S, et al.
- Journal Title
  
  Cancer Res
  
  Volume: 79(7) Issue: 7 Pages: 1658-1670
- DOI
  10.1158/0008-5472.can-18-2052
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-16H05308, KAKENHI-PROJECT-16H04715, KAKENHI-PROJECT-17K09649, KAKENHI-PROJECT-19K07346, KAKENHI-PROJECT-19H03665
[Journal Article] Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status2019
- Author(s)
  Koji Fukuda, Shinji Takeuchi, Sachiko Arai, Ryohei Katayama, et al
- Journal Title
  
  Cancer Reseach
  
  Volume: 79 Pages: 1658-1670
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-18K07261
[Journal Article] Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status.2019
- Author(s)
  Fukuda K, Takeuchi S, Arai S, Katayama R, Nanjo S, Tanimoto A, Nishiyama A, Nakagawa T, Taniguchi H, Suzuki T, Yamada T, Nishihara H, Ninomiya H, Ishikawa Y, Baba S, Takeuchi K, Horiike A, Yanagitani N, Nishio M, Yano S.
- Journal Title
  
  Cancer Resarch
  
  Volume: 79 Pages: 1658-1670
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-18K07261
[Journal Article] Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC.2018
- Author(s)
  Arasada RR, Shilo K, Yamada T, Zhang J, Yano S, Ghanem R, Wang W, Takeuchi S, Fukuda K, Katakami N, Tomii K, Ogushi F, Nishioka Y, Talabere T, Misra S, Duan W, Fadda P, Rahman MA, Nana-Sinkam P, Evans J, Amann J, Tchekneva EE, Dikov MM, Carbone DP.
- Journal Title
  
  Nat Commun.
  
  Volume: 9 Issue: 1 Pages: 3198-3198
- DOI
  10.1038/s41467-018-05626-2
- NAID
  120006949473
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17K09649
[Journal Article] Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K, Yano S.2018
- Author(s)
  Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K, Yano S.
- Journal Title
  
  Nat Commun.
  
  Volume: 10 Issue: 1 Pages: 259-259
- DOI
  10.1038/s41467-018-08074-0
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17K09649, KAKENHI-PROJECT-16H05308, KAKENHI-PROJECT-18KT0019, KAKENHI-PROJECT-19K08608, KAKENHI-PROJECT-19H03665
[Journal Article] Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer.2017
- Author(s)
  Tanimoto A, Takeuchi S, Arai S, Fukuda K, Yamada T, Roca X, Ong ST, Yano S.
- Journal Title
  
  Clin Cancer Res.
  
  Volume: 23 Issue: 12 Pages: 3139-3149
- DOI
  10.1158/1078-0432.ccr-16-2271
- Peer Reviewed / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17K09649
[Journal Article] Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway.2017
- Author(s)
  Taniguchi H, Yamada T, Takeuchi S, Arai S, Fukuda K, Sakamoto S, Kawada M, Yamaguchi H, Mukae H, Yano S.
- Journal Title
  
  Cancer Sci.
  
  Volume: 108 Issue: 7 Pages: 1378-1385
- DOI
  10.1111/cas.13268
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-17K09649, KAKENHI-PROJECT-16H05308, KAKENHI-PROJECT-15K06888
[Journal Article] Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation.2017
- Author(s)
  Takeuchi S, Fukuda K, Yamada T, Arai S, Takagi S, Ishii G, Ochiai A, Iwakiri S, Itoi K, Uehara H, Nishihara H, Fujita N, Yano S.
- Journal Title
  
  Cancer Sci.
  
  Volume: 108 Issue: 4 Pages: 696-703
- DOI
  10.1111/cas.13190
- NAID
  120006306235
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-17K09649, KAKENHI-PROJECT-16H05308
[Journal Article] In vivo imaging xenograft models for the evaluation of anti-brain tumor efficacy of targeted drugs.2017
- Author(s)
  Kita K, Arai S, Nishiyama A, Taniguchi H, Fukuda K, Wang R, Yamada T, Takeuchi S, Tange S, Tajima A, Nakada M, Yasumoto K, Motoo Y, Murakami T, Yano S.
- Journal Title
  
  Cancer Med
  
  Volume: 6 Issue: 12 Pages: 2972-2983
- DOI
  10.1002/cam4.1255
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-17K09649, KAKENHI-PROJECT-16H05308, KAKENHI-PROJECT-26461700, KAKENHI-PROJECT-15K13100
[Journal Article] Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J): a study protocol2017
- Author(s)
 Takeuchi S, Yoshimura K, Fujiwara T, Ando M, Shimizu S, Nagase K, Hasegawa Y, Takahashi T, Katakami N, Inoue A, Yano S.
- Journal Title
 
 J. Med. Invest.
 
 Volume: 64 Issue: 3.4 Pages: 321-325
- DOI
 10.2152/jmi.64.321
- NAID
 130006105349
- ISSN
 1343-1420, 1349-6867
- Language
 English
- Data Source
 KAKENHI-PROJECT-17K09649
[Journal Article] In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.2015
- Author(s)
  Nanjo S, Yano S, et al.
- Journal Title
  
  Cancer Sci
  
  Volume: 106 Issue: 3 Pages: 244-52
- DOI
  10.1111/cas.12600
- NAID
  120005830611
- Peer Reviewed / Acknowledgement Compliant / Open Access
- Data Source
  KAKENHI-PLANNED-22112010, KAKENHI-PLANNED-23112101, KAKENHI-PROJECT-24390209, KAKENHI-PROJECT-24650625, KAKENHI-PROJECT-24659403, KAKENHI-PROJECT-25860640, KAKENHI-PROJECT-26250028, KAKENHI-PROJECT-26293322, KAKENHI-PROJECT-25462190, KAKENHI-PROJECT-25462202
[Journal Article] Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: Sensitivity and resistance.2014
- Author(s)
  Takeuchi S, Yano S.
- Journal Title
  
  Respir Investig
  
  Volume: 52 Issue: 6 Pages: 348-56
- DOI
  10.1016/j.resinv.2014.10.002
- Peer Reviewed / Acknowledgement Compliant / Open Access
- Data Source
  KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-25860640
[Journal Article] Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells.2014
- Author(s)
  Tanimoto A, Yamada T, Nanjo S, Takeuchi S, Ebi H, Kita K, Matsumoto K, Yano S.
- Journal Title
  
  Oncotarget
  
  Volume: 5 Pages: 4920-4928
- NAID
  120005830567
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-25860640
[Journal Article] Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.2013
- Author(s)
  Nanjo S, Yamada T, Nishihara H, Takeuchi S, Sano T, Nakagawa T, Ishikawa D, Zhao L, Ebi H, Yasumoto K, Matsumoto K, Yano S.
- Journal Title
  
  PLoS One
  
  Volume: 8
- NAID
  120005368227
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-25860640
[Journal Article] EGFR-TKI resistance due to BIM polymorphism can be circumvented　in　combination with HDAC inhibition.2013
- Author(s)
  Nakagawa T, Yano S, et al.
- Journal Title
  
  Cancer Res
  
  Volume: 73 Issue: 8 Pages: 2428-34
- DOI
  10.1158/0008-5472.can-12-3479
- Peer Reviewed
- Data Source
  KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-23790902, KAKENHI-PROJECT-24390209, KAKENHI-PROJECT-25860638, KAKENHI-PROJECT-25860640, KAKENHI-ORGANIZER-22112001
[Journal Article] The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.2013
- Author(s)
  Sano T, Yano S, et al.
- Journal Title
  
  Int J Cancer
  
  Volume: 133 Issue: 2 Pages: 505-13
- DOI
  10.1002/ijc.28034
- Peer Reviewed
- Data Source
  KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-23790327, KAKENHI-PROJECT-23790903, KAKENHI-PROJECT-24300329, KAKENHI-PROJECT-24390209, KAKENHI-PROJECT-25860638
[Journal Article] mTOR inhibitors control erlotinib-resistance of EGFR mutant lung cancer cells triggered by HGF.2013
- Author(s)
  Ishikawa D, Yano S, et al.
- Journal Title
  
  PLoS ONE
  
  Volume: 8 Issue: 5 Pages: e62104-e62104
- DOI
  10.1371/journal.pone.0062104
- Peer Reviewed
- Data Source
  KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-23591141, KAKENHI-PROJECT-24300329, KAKENHI-PROJECT-24390209, KAKENHI-PROJECT-24591156, KAKENHI-PROJECT-25860638, KAKENHI-PROJECT-25860640
[Journal Article] Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer.2013
- Author(s)
  Zhao L, Yano S, et al.
- Journal Title
  
  Cancer Sci
  
  Volume: 104 Issue: 12 Pages: 1640-6
- DOI
  10.1111/cas.12301
- NAID
  120005830610
- Peer Reviewed
- Data Source
  KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-23501273, KAKENHI-PROJECT-23591632, KAKENHI-PROJECT-23591921, KAKENHI-PROJECT-24300329, KAKENHI-PROJECT-24390209, KAKENHI-PROJECT-25860640
[Journal Article] Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer2012
- Author(s)
  Nakagawa T
- Journal Title
  
  Mol Cancer Ther.
  
  Volume: 11 Issue: 10 Pages: 2149-2157
- DOI
  10.1158/1535-7163.mct-12-0195
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23790327, KAKENHI-PROJECT-23790902, KAKENHI-PROJECT-23790903, KAKENHI-PROJECT-24300329, KAKENHI-PROJECT-24659403
[Journal Article] Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer2012
- Author(s)
  Yamada T, Takeuchi S, Kita K, Bando H, Nakamura T, Matsumoto K, Yano S
- Journal Title
  
  J Thorac Oncol
  
  Volume: 7 Issue: 2 Pages: 272-80
- DOI
  10.1097/jto.0b013e3182398e69
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21390256, KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-23790327, KAKENHI-PROJECT-23790902, KAKENHI-PROJECT-24300329, KAKENHI-PROJECT-24390209
[Journal Article] E7050, a Met kinase inhibitor, reverses three different mechanisms of hepatocyte growth factor-induced resistance to tyrosine kinase inhibitors in EGFR mutant lung cancer cells2012
- Author(s)
  Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, Nakamura T, Matsumoto K, Mukaida N, Nishioka Y, Sone S, Uenaka T, Yano S
- Journal Title
  
  Clin Cancer Res
  
  Volume: 18 Issue: 6 Pages: 1663-71
- DOI
  10.1158/1078-0432.ccr-11-1171
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21390256, KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-22390166, KAKENHI-PROJECT-23790327, KAKENHI-PROJECT-23790902, KAKENHI-PROJECT-23790903, KAKENHI-PROJECT-24300329, KAKENHI-PROJECT-24390209, KAKENHI-PROJECT-24390210
[Journal Article] Dual inhibition of met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer2012
- Author(s)
  Takeuchi S, Wang W, Li Q, Yamada T, Kita K, Donev IS, Nakamura T, Matsumoto K, Shimizu E, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano
- Journal Title
  
  Am J Pathol
  
  Volume: 181 Issue: 3 Pages: 1034-1043
- DOI
  10.1016/j.ajpath.2012.05.023
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-22390166, KAKENHI-PROJECT-23790327, KAKENHI-PROJECT-23790902, KAKENHI-PROJECT-23790903, KAKENHI-PROJECT-24300329, KAKENHI-PROJECT-24390210, KAKENHI-PROJECT-24659403
[Journal Article] Ligand-triggered resistance to molecular targeted drugs in lung cancer : roles of HGF and EGFR ligands2012
- Author(s)
  Yano S, Takeuchi S, Nakagawa T, Yamada T
- Journal Title
  
  Cancer Sci
  
  Volume: (In press) Issue: 7 Pages: 1189-1194
- DOI
  10.1111/j.1349-7006.2012.02279.x
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21390256, KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-23790902, KAKENHI-PROJECT-23790903
[Journal Article] Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells2012
- Author(s)
  Yamada, T.
- Journal Title
  
  Clin. Cancer Res.
  
  Volume: 18 Issue: 13 Pages: 3592-3602
- DOI
  10.1158/1078-0432.ccr-11-2972
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23689043, KAKENHI-PROJECT-23790327, KAKENHI-PROJECT-23790902, KAKENHI-PROJECT-23790903, KAKENHI-PROJECT-24300329, KAKENHI-PROJECT-24659403
[Journal Article] Akt kinase-interacting　protein1, a novel therapeutic target for lung cancer with EGFR activating and gatekeeper mutations.2012
- Author(s)
  Yamada T, Takeuchi S, et al.
- Journal Title
  
  Oncogene.
  
  Volume: Epub ahead of print
- NAID
  120004997024
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23790903
[Journal Article] Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR mutant lung cancer by decreasing client protein expression and angiogenesis2012
- Author(s)
  Koizumi H, Yamada T, Takeuchi S, Nakagawa T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Yano S.
- Journal Title
  
  J Thorac Oncol
  
  Volume: (in press)
- NAID
  40019570662
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21390256
[Journal Article] Hsp90 Inhibition Overcomes HGF Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis2012
- Author(s)
  Koizumi H, Yamada T, Takeuchi S, Nakagawa T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, and Yano S
- Journal Title
  
  Journal of Thoracic Oncology
  
  Volume: Vol. 7: no.7 Issue: 7 Pages: 1078-1085
- DOI
  10.1097/jto.0b013e3182519a2c
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23790327, KAKENHI-PROJECT-23790902, KAKENHI-PROJECT-23790903, KAKENHI-PROJECT-24300329, KAKENHI-PROJECT-24390209, KAKENHI-PROJECT-24659403, KAKENHI-PLANNED-22112010
[Journal Article] Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer2011
- Author(s)
  Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S
- Journal Title
  
  Clin Cancer Res
  
  Volume: 17 Issue: 8 Pages: 2260-9
- DOI
  10.1158/1078-0432.ccr-10-1993
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21390256, KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-22240092, KAKENHI-PROJECT-23790902, KAKENHI-PROJECT-23790903
[Journal Article] The EGFR ligands amphiregulin and heparin-binding EGF-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer2011
- Author(s)
  Yasumoto K, Yamada T, Kawashima A, Wang W, Li Q, Donev IS, Takeuchi S, Mouri H, Yamashita K, Ohtsubo K, Yano S.
- Journal Title
  
  Clin Cancer Res
  
  Volume: 17 Issue: 11 Pages: 3619-30
- DOI
  10.1158/1078-0432.ccr-10-2475
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21390256, KAKENHI-ORGANIZER-22112001, KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-23591921, KAKENHI-PROJECT-23790902
[Journal Article] Genetically engineered humanized anti-ganglioside GM2 anti-body against multiple organ metastasis produced by GM2 expressing small cell lung cancer2011
- Author(s)
  Yamada T, Bando H, Takeuchi S, Kita K, Li Q, Wang W, Akinaga S, Nishioka Y, Sone S, Yano S.
- Journal Title
  
  Cancer Sci
  
  Volume: 102 Issue: 12 Pages: 2157-63
- DOI
  10.1111/j.1349-7006.2011.02093.x
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21390256, KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-22390166, KAKENHI-PROJECT-23790902, KAKENHI-PROJECT-23790903
[Journal Article] Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort2011
- Author(s)
  Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, Nokihara H, Ohe Y, Yokota J, Uramoto U, Yasumoto Y, Kiura K, Higashiyama M, Oda M, Saito H, Yoshida J, Kondoh K, Noguchi M.
- Journal Title
  
  J Thorac Oncol
  
  Volume: 6 Issue: 12 Pages: 2011-7
- DOI
  10.1097/jto.0b013e31823ab0dd
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21390256, KAKENHI-PROJECT-21591831, KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-23790902, KAKENHI-PROJECT-23790903
[Journal Article] E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor2011
- Author(s)
  Ogino H, Hanibuchi M, Kakiuchi S, Trung Van The, Goto H, Ikuta K, Yamada T, Uehara H, Tsuruoka A, Uenaka T, Wang W, Li Q, Takeuchi S, Yano S, Nishioka Y, Sone S.
- Journal Title
  
  Mol Cancer Ther
  
  Volume: 10 Issue: 7 Pages: 1218-28
- DOI
  10.1158/1535-7163.mct-10-0707
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21390256, KAKENHI-PLANNED-22112010, KAKENHI-PROJECT-22390166, KAKENHI-PROJECT-23790902, KAKENHI-PROJECT-23790903
[Presentation] ALK融合遺伝子陽性肺がんにおけるSTAT3阻害薬の併用によるアポトーシス抵抗性の克服2021
- Author(s)
  柳村尚寛、竹内伸司、新井祥子、福田康二、西山明宏、矢野聖二
- Organizer
  第25回日本分子標的治療学会
- Data Source
  KAKENHI-PROJECT-20K08516
[Presentation] 肺癌のアポトーシス抵抗性に起因する分子標的薬耐性を克服する橋渡し研究2018
- Author(s)
  竹内伸司
- Organizer
  第77回日本癌学会学術総会
- Data Source
  KAKENHI-PROJECT-17K09649
[Presentation] ALK転座陽性肺癌においてEMTは独立した機構として関与する2018
- Author(s)
  福田康二、竹内伸司、片山量平、南條成輝、山田忠明、鈴木健之、竹内健吾、西尾誠人、矢野聖二
- Organizer
  第77回日本癌学会学術総会 2018
- Data Source
  KAKENHI-PROJECT-18K07261
[Presentation] New therapeutic strategies for overcoming resistance to targeted drugs in lung cancer by HDAC inhibition2017
- Author(s)
  竹内伸司
- Organizer
  第76回日本癌学会学術総会
- Invited
- Data Source
  KAKENHI-PROJECT-17K09649
[Presentation] 医師主導治験による肺がんの新規分子標的治療の開発2017
- Author(s)
  竹内伸司
- Organizer
  第15回日本臨床腫瘍学会学術集会
- Data Source
  KAKENHI-PROJECT-17K09649
[Presentation] HDAC inhibition overcomes crizotinib-resistance by inducing mesenchymal-epithelial reverting transition (MERT) via miR-200c up-regulation in EML4-ALK lung cancer cells.2016
- Author(s)
  Koji Fukuda, Shigeki Nanjo, Shinji Takeuchi, Tadaaki Yamada, Ryohei Katayama, Kengo Takeuchi, Hiroshi Nishihara, Seiji Yano.
- Organizer
  Tenth AACR-JCA Joint Conference
- Place of Presentation
  Maui, Hawaii, USA
- Year and Date
  2016-02-16
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-26860603
[Presentation] 分子標的薬に対する側副経路活性化による耐性メカニズム2012
- Author(s)
  竹内伸司, 矢野聖二
- Organizer
  日本がん分子標的治療学会第16回学術集会
- Year and Date
  2012-06-28
- Data Source
  KAKENHI-PROJECT-23790903
[Presentation] 分子標的薬に対する側副経路活性化による耐性メカニズム2012
- Author(s)
  竹内伸司
- Organizer
  日本がん分子標的治療学会第16回学術集会
- Place of Presentation
  北九州市西日本総合展示場
- Data Source
  KAKENHI-PROJECT-23790903
[Presentation] Dual Inhibition of Met Kinase and Angiogenesis to Overcome HGF-induced EGFR-TKI Resistance in EGFR Mutant Lung Cancer2011
- Author(s)
  竹内　伸司
- Organizer
  第70回日本癌学会学術総会
- Place of Presentation
  名古屋国際会議場(愛知県)
- Data Source
  KAKENHI-PROJECT-23790903
[Presentation] Met/VEGFR-2阻害剤E7050は変異型EGFR肺がんにおいてHGFによるEGFR-TKI耐性誘導を克服する2011
- Author(s)
  竹内伸司, Wang Wei, Li Qi, 山田忠明, Donev Ivan, 小泉瞳, 中村隆弘, 松本邦夫, 西岡安彦, 曽根三郎, 上仲俊光, 矢野聖二
- Organizer
  第70回日本がん学会学術総会
- Year and Date
  2011-10-03
- Data Source
  KAKENHI-PROJECT-23790903
[Presentation] Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. 2011 American Society of Clinical Oncology(ASCO)2011
- Author(s)
  Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, Nokihara H, Ohe Y, Yokota J, Uramoto H, Yasumoto K, Kiura K, Higashiyama M, Oda M, Saito H, Yoshida J, Kondoh K
- Organizer
  Annual Meeting
- Place of Presentation
  McCormick Place(USA.)
- Year and Date
  2011-06-04
- Data Source
  KAKENHI-PROJECT-21390256
[Presentation] EGFR-TKI耐性とその克服
- Author(s)
  竹内伸司、矢野聖二
- Organizer
  第18回日本がん分子標的治療学会学術集会
- Place of Presentation
  仙台
- Year and Date
  2014-06-25 – 2014-06-27
- Data Source
  KAKENHI-PROJECT-25860640
[Presentation] BIM遺伝子多型に起因するEGFR-TKI耐性とHDAC阻害薬併用による耐性克服治療戦略
- Author(s)
  竹内伸司,　中川学之,　長谷川好規,　矢野聖二
- Organizer
  第54回日本肺癌学会総会
- Place of Presentation
  東京
- Invited
- Data Source
  KAKENHI-PROJECT-25860640
[Presentation] EGFR変異肺がんのEGFR-TKI耐性
- Author(s)
  竹内伸司、矢野聖二
- Organizer
  第54回日本呼吸器学会学術講演
- Place of Presentation
  大阪
- Year and Date
  2014-04-25 – 2014-04-27
- Data Source
  KAKENHI-PROJECT-25860640
[Presentation] BIM遺伝子多型に起因する分子標的薬耐性の克服
- Author(s)
  竹内伸司, 中川学之, 矢野聖二
- Organizer
  第11回日本臨床腫瘍学会学術集会
- Place of Presentation
  仙台
- Invited
- Data Source
  KAKENHI-PROJECT-25860640
[Presentation] Therapeutic strategies for overcoming resistance to EGFR-TKI and ALK-TKI by inhibition of Hsp90 or HADC
- Author(s)
  竹内伸司、矢野聖二
- Organizer
  第12回日本臨床腫瘍学会学術集会
- Place of Presentation
  福岡
- Year and Date
  2014-07-17 – 2014-07-19
- Data Source
  KAKENHI-PROJECT-25860640
[Presentation] EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition
- Author(s)
  Takeuchi S, Nakagawa T, Yamada T, Yano S.
- Organizer
  IASLC 15th World Conference on Lung Cancer
- Place of Presentation
  シドニー
- Invited
- Data Source
  KAKENHI-PROJECT-25860640
[Presentation] BIM遺伝子多型によるEGFR-TKI耐性の治療法開発の現状
- Author(s)
  竹内伸司、矢野聖二
- Organizer
  第55回日本肺癌学会学術集会
- Place of Presentation
  京都
- Year and Date
  2014-11-14 – 2014-11-16
- Data Source
  KAKENHI-PROJECT-25860640
[]

1. YANO Seiji (30294672)

# of Collaborated Projects: 2 results

# of Collaborated Products: 18 results
2. Fukuda Koji (10722548)

# of Collaborated Projects: 2 results

# of Collaborated Products: 5 results
3. WANG Wei (80467117)

# of Collaborated Projects: 1 results

# of Collaborated Products: 5 results
4. YAMADA Tadaaki (00507048)

# of Collaborated Projects: 1 results

# of Collaborated Products: 10 results
5. 菊地利明

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
6. 阿部貴志

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
7. 曽根三郎

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
8. 西岡安彦

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
9. 中村隆弘

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results

Takeuchi Shinji 竹内 伸司

TAKEUCHI SHINJI 竹内 伸司

TAKEUCHI Shinji 竹内 伸司

Research Projects

Research Products

Co-Researchers

Development of Novel Therapies Targeting Apoptosis Resistance Factors in ALK-rearranged Lung CancerPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Development of treatment to overcome TKI resistance caused by EMT in lung cancer

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Development of therapy for overcoming resistance to mutant selective EGFR-TKI due to persistance of apoptosisPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Development of therapies for overcoming EMT-associated irreversible tyrosine kinase inhibitor resistance in EGFR lung cancer

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Development of therapy for circumvention of EGFR-TKI resistance due to BIM polymorphism in EGFR mutant lung cancer.Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Development of novel targeted therapy for lung cancer with activating Ras mutationPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Development of individual therapy for overcoming HGF-induced molecular targeted drug-resistance in EGFR-mutant lung cancer

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Book] 分子呼吸器病2014

Author(s)

Publisher

Data Source

[Book] Biotherapy 25巻5号2011

Author(s)

Publisher

Data Source

[Journal Article] STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis.2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)2021

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.2020

Author(s)

Journal Title

DOI

Data Source

[Journal Article] MET amplification results in heterogeneous responses to osimertinib in EGFR ‐mutant lung cancer treated with erlotinib2020

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with <i>BIM</i> deletion polymorphism2020

Author(s)

Journal Title

DOI

Takeuchi Shinji 竹内伸司

TAKEUCHI SHINJI 竹内伸司

TAKEUCHI Shinji 竹内伸司